Clinical

Clinical  ·  Weekly Digest 22 March to 28 March 2025
Innovent dosed first participant in Phase 3 clinical study of IBI354 (novel HER2 ADC) for platinum-resistant ovarian cancer

Weekly Digest – March 2025 Weekly Digest – March 2025 24 Mar 2025: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer Innovent Biologics has successfully dosed the first participant in […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 22 March to 28 March 2025
MacroGenics pulls plug on Vobra duo ADC after seeing Phase 2 Prostate cancer data

Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: MacroGenics pulls plug on Vobra duo ADC after seeing phase 2 prostate cancer data MacroGenics decided to halt the development of Vobramitamab duocarmazine (Vobra duo) after reviewing […]

by Sandhya Ramalingam

Continue Reading